Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
11.12+0.17 (+1.55%)
At close: 04:00PM EDT
11.20 +0.08 (+0.72%)
After hours: 06:52PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • W
    William H.
    When oral Korsuva reaches the market---physicians will use it like a safe long term steroid controlling pruritus as well as chronic pain with other drugs since no interactions
  • B
    Billy McGinty
    What is up with the price action in the ah/pm? it's always been all outta sorts, but down 3.99 on 25 shares?
  • B
    Ben
    7 million shares shorted/15% of Float...
    Bullish
  • S
    Stan
    Breakeven Analysis: Target $0.0 EPS (Just K-IV US sales - excluding Kapruvia, ACSS sales, and pipeline)

    To breakeven based on a quarterly expense run rate of $32M, or report $0.00 EPS, they need to sell K-IV in the US to cover ~12,000 patients (based on administration of 3 vials/week, 12 week quarters at $150). This would be the baseline to help immunize the fluctuating and variability of the milestone payments.

    This is achievable given the US CKD-Ap population of 150,000-200,000
  • B
    Ben
    Looking better and better each quarter. Doesn't mean this wont drop back down to $9 for no reason at all but it does confirm why so many of us have been hanging around for years ;)

    Second Quarter and Recent Developments:

    KORSUVA Injection: Chronic Kidney Disease-Associated Pruritus: Hemodialysis

    In April 2022, the Company and its commercial partner, Vifor, launched KORSUVA (difelikefalin) injection in the U.S. for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. KORSUVA injection generated net sales of $16.8 million in the second quarter of 2022, translating into $8 million in profit-sharing revenue for Cara. Wholesalers shipped 1,812 vials driven by independent and midsize dialysis organizations.

    In the second quarter, the Company received the $15 million regulatory milestone payment triggered by the April 2022 European Commission approval of Kapruvia® (difelikefalin) for the treatment of moderate-to-severe pruritus associated with CKD in adult hemodialysis patients. Also in April 2022, Kapruvia was approved in the UK. The Company expects the commercial launches of Kapruvia to commence in certain European markets in the second half of 2022.

    Second Quarter 2022 Financial Results

    Cash, cash equivalents and marketable securities at June 30, 2022 totaled $204.7 million compared to $236.8 million at December 31, 2021. The decrease in the balance primarily resulted from $30.0 million of cash used in operating activities.

    For the second quarter of 2022, net loss was $4.2 million, or $(0.08) per basic and diluted share, compared to net loss of $30.7 million, or ($0.61) per basic and diluted share, for the same period in 2021.

    Revenues: Total revenue was $23.0 million for the three months ended June 30, 2022. There was no revenue during the same period of 2021. Revenue consisted of:

    $15.0 million of license and milestone fees revenue, related to the regulatory milestone payment for the approval of Kapruvia by the European Commission in April 2022 during the three months ended June 30, 2022; and

    $8.0 million of collaborative revenue, related to the profit-sharing revenue from Vifor’s sales of KORSUVA injection to third parties during the three months ended June 30, 2022.
    Bullish
  • W
    William H.
    Perhaps If the market removes CARA from the marijuana stocks and puts it into drug stocks---If $ 21.3 million is accurate sales in 3 months of marketing THAT is pretty good---this is just 3500 to 4000 patients and the market is closer to 200,000--so a long way to go yet--$150 per vial of korsuva iv
  • W
    William H.
    Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M
  • e
    edwint
    News Out!!!!!!
    Up big in premarket!!!
  • S
    Stan
    Had they not had the milestone payment for the EU approval of Kapruvia ($15M), revenues would simply have been $8M. Without the milestone payment from Enteris ($10M), R&D costs would have been closer to $37M and not $27M. And EPS would have been closer to -$0.54 vs the analyst estimate of -$0.25

    I had expected -$0.03 with the $15M milestone payment from the ACSS nations but this remains outstanding.

    Overall a good quarter.
  • W
    William H.
    CARA and Vifor have no control of the 2800 Fresenius dialysis centers' time table for training and set up for the use of Korsuva IV. Vifor did a great job getting the MDC and SDC on line selling $17 million worth of Korsuva in 3 months--these sales are on going- so the Stable state sales of Korsuva IV will be at least $ 30 million (guess) next quarter and growing rapidly to cover potentially 200,000 patients
  • S
    Suazo
    Yahoo! has been so bad lately - especially the CARA board. I like using (http://Themaxgains.tech) now instead for my daily research.
  • A
    Anonymous
    Maybe the slow rollout of Korsuva has more to do with the Vifor/CSL merger than it does with CARA or their product? Just a thought.
  • S
    Steve
    23 Mil - not bad
  • W
    William H.
    the Big Dialysis Centers 75% of the market are just now ordering Korsuva IV due to set up and staff training the $ 17 million in total sales vifor made was to moderate and small dialysis centers ---CARA will be a money machine as the 200,000 patient pruritus sufferers get relief
  • C
    Chris
    Come on baby back to $9 please I feel like loading up now and holding for a couple of years.
  • B
    Billy McGinty
    Wainwright's got a $30 price target
    $$$
    Bullish
  • S
    Stan
    By my calculations, based on the $16.8M of product, I also arrive at a inventory supply equivalent to 3,111 patients for the quarter.

    Additionally, the 1,812 vials distributed is also the equivalent to K-IV administration to a mere 50 patients which is low. I suspect that this may have been a test/launch at a single dialysis center.
  • J
    Jeffrey
    Chris- so it looks like CKD-oral will be completed the 2nd half of 2024 and the first half of the study on AD (KIND 1) will have read out in 2nd half of 2023 and then the KIND 2 will take place from 2023 to when? its only a 12 week study - how could it go to 2026?
  • T
    Thomas
    keep it going !
    Bullish
Advertisement
Advertisement